Path Fertility, the commercial brand of Salt Lake City-based Inherent Biosciences, Inc., has received a $2 million grant from ...
Full Cohort 2 results will be presented at an upcoming medical meeting. Cohort 3 of the PROGRESS study, which is evaluating zilurgisertib in pediatric patients aged 2 to <12 years, is currently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results